Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
34 results
D2.521 - Reshaping Allergy Assessment Pathways In The United Kingdom: Modeling System-Level Gains Through Discrete Event Simulation
D2.522 - An Observational Study of techniques of Intanasal Spray in Allergic Rhinitis
D2.524 - How much does wheat oral immunotherapy improve quality of life?
D2.530 - Digital patient-reported data uncover key clinical features of mastocytosis: insights from the MASTHAVE App
D2.532 - Does Bathing Frequency Matter in Pediatric Atopic Dermatitis? Insights from Real-Life Practice
D2.533 - Characterizing Elderly Asthma Hospitalizations: Insights into Treatment Gaps and Outcomes; A Real‑World Study Using the MIMIC‑IV Dataset
D2.523 - Dyadic parenting stress and marital communication among parents of young children with food allergies
D2.527 - Lessening the food allergy burden through education: A Canadian focus
D2.528 - Corticophobia Among Caregivers of Children with Atopic Diseases: Causes and Outcomes
D2.529 - Asymptomatıc QT Prolongatıon Developıng After Antıhıstamıne Use
D2.531 - Expert Panel Discussion on a New Oral On-Demand Treatment in Hereditary Angioedema
D2.536 - Seasonal Influenza Vaccination: Uptake Rate, Profile, and Motivating Factors Among Healthcare Workers
D2.537 - Advances in Drug Allergy & Penicillin Testing Phase 2 (ADAPT-2): an AI-powered drug allergy educational initiative spanning across 4 localities
D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study
D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download